Bharat Immunologicals & Biologicals Corp. Ltd.

As of September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. has 43.18M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 13.70, and the price-to-book ratio stands at 1.33.

These figures are as of September 30, 2023. The EV/Sales ratio of 22.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.70B versus a market cap of 1.05B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.48, indicating elevated leverage, while an interest coverage ratio of -2.87 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. posted a negative return on equity (ROE) of -20.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.05, reflecting losses generated across the asset base. Inventory turnover of 2.02 indicates how many times Bharat Immunologicals & Biologicals Corp. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. recorded an income tax benefit of -65.54M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -246.19M and -180.65M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Bharat Immunologicals & Biologicals Corp. Ltd.'s stock has declined approximately 55.72% over the past 52 weeks. The 50-day moving average sits at 13.05, while the 200-day moving average is 16.34.

Over the twelve months ended September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. generated 76.50M in revenue and converted that into -180.65M in net income, yielding earnings per share of -4.18. EBITDA reached -214.03M, while operating income came in at -215.98M.

As of September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. holds 89.09M in cash and equivalents against 743.64M in total debt, resulting in a net debt position of 729.06M. Total book value stands at 787.09M, with working capital of -663.45M providing operational flexibility.

Over the twelve months ended September 30, 2023, Bharat Immunologicals & Biologicals Corp. Ltd. posted a gross margin of -27.35, reflecting its pricing power and cost economics. The operating margin of -282.31 and net profit margin of -236.13 provide insight into operational efficiency.